Quantum Capital Management LLC NJ Has $49.37 Million Stake in IDEXX Laboratories, Inc. $IDXX

Key Points

• Quantum Capital Management LLC NJ increased its holdings in IDEXX Laboratories by 110.4% in the first quarter, making IDEXX its 10th largest position with a total investment value of approximately $49.37 million.
• IDEXX Laboratories reported earnings of $3.63 per share for the quarter, surpassing analyst estimates of $3.28, while revenue reached $1.11 billion, up 10.6% year-over-year.
• Insiders sold a total of 51,870 shares of IDEXX Laboratories stock in the last quarter, amounting to over $32.87 million, resulting in a significant decrease in their ownership stakes.

Quantum Capital Management LLC NJ grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 110.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 117,567 shares of the company's stock after purchasing an additional 61,684 shares during the quarter. IDEXX Laboratories makes up approximately 5.1% of Quantum Capital Management LLC NJ's holdings, making the stock its 10th biggest holding. Quantum Capital Management LLC NJ owned about 0.15% of IDEXX Laboratories worth $49,372,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. MorganRosel Wealth Management LLC acquired a new stake in IDEXX Laboratories during the first quarter worth about $26,000. Migdal Insurance & Financial Holdings Ltd. raised its stake in IDEXX Laboratories by 55.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock worth $35,000 after acquiring an additional 30 shares during the period. Colonial Trust Co SC raised its stake in IDEXX Laboratories by 84.8% during the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after acquiring an additional 39 shares during the period. Bank of Jackson Hole Trust raised its stake in IDEXX Laboratories by 328.6% during the first quarter. Bank of Jackson Hole Trust now owns 90 shares of the company's stock worth $39,000 after acquiring an additional 69 shares during the period. Finally, Itau Unibanco Holding S.A. raised its stake in IDEXX Laboratories by 540.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after acquiring an additional 81 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded down $3.7050 on Monday, hitting $641.8450. The stock had a trading volume of 110,252 shares, compared to its average volume of 718,053. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The stock has a market cap of $51.35 billion, a price-to-earnings ratio of 53.46, a P/E/G ratio of 4.18 and a beta of 1.49. The company's 50-day moving average is $569.94 and its two-hundred day moving average is $494.38.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The firm had revenue of $1.11 billion during the quarter, compared to analysts' expectations of $1.06 billion. During the same quarter in the prior year, the firm earned $2.44 EPS. IDEXX Laboratories's quarterly revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analyst Weigh In

IDXX has been the topic of several research reports. Jefferies Financial Group initiated coverage on shares of IDEXX Laboratories in a research note on Tuesday, July 1st. They set a "buy" rating and a $625.00 price objective on the stock. BTIG Research increased their price objective on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Morgan Stanley increased their price objective on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the stock an "overweight" rating in a research note on Friday, August 15th. Wall Street Zen upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. Finally, JPMorgan Chase & Co. upped their target price on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the stock an "overweight" rating in a research report on Monday, August 4th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $649.44.

Insiders Place Their Bets

In other news, EVP Nimrata Hunt sold 7,143 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $630.43, for a total value of $4,503,161.49. Following the completion of the transaction, the executive vice president directly owned 18,007 shares in the company, valued at $11,352,153.01. This trade represents a 28.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael G. Erickson sold 406 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total transaction of $263,883.76. Following the completion of the transaction, the executive vice president owned 11,287 shares of the company's stock, valued at $7,336,098.52. This trade represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 51,870 shares of company stock valued at $32,877,757. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.